Keywords: UK, NICE, Roche, Avastin, Breast cancer, Bone cancer, Takeda, Mepact

Roche’s Avastin rejected by UK’s NICE in draft guidance due to “uncertain evidence base;” Takeda’s Mepact turned down on cost and efficacy

Article | 12 July 2010

Print This

In a third rejection for the Swiss drug major Roche within a matter of weeks, the UK National Health service ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in